DS MEDIDATA

Rave Lite for Phase I Trials

The Medidata solutions you already know and trust on more flexible terms for your Phase I trials.

Recognized as the industry leader in Everest Group's 2024 Peak Matrix Life Sciences Electronic Data Capture

Medidata understands the challenges of Phase I clinical trials and the need to protect your investment in a new compound. In response, Medidata offers a tailored, cost-effective offering for your Phase I trials. Achieve your goals with faster and more efficient study builds that ensure your trial starts on schedule. Rave Lite for Phase I Trials enables you to transition rapidly and seamlessly from Phase I to planning the next phase of your trial.

Benefits of Rave Lite for Phase I Trials

Streamline Study Build

Build studies faster and more accurately using a pre-configured, pre-validated, and accelerated implementation service.

- Leverage standard configured libraries containing typical Phase I forms, fields, edit checks, custom functions with basic visit structure and dynamics, and lab administration.

- Quickly match your trial design in our Randomization and Trial Supply Management (RTSM) tool to allow simple kit selection/assignment within EDC, titration tracking, and streamlining your dose-finding activities.

- Experience rapid deployments and upgrades, reduced study build times, and faster database lock.

- Automate the process of assigning and tracking your investigational product.

Pay Only for What You Need

Invest in the technology you require. Benefit from Medidata's expertise and offerings, tailored specifically to your trials, precisely when and how you need it.

- Maximize cost efficiency with pricing scaled appropriately for Phase I studies' smaller size and budget.

- Tailor to the size or complexity of your Phase I trial.

- Accelerate your early-stage trials to match your timelines.

Benefits of Rave for Phase I Trials

Affordable Scalability, Superior Functionality

Benefit from Rave's optimized capabilities for your unique trial needs. Medidata can scale and pivot as your needs grow from your Phase I protocol to your Phase II planning.

- Scale from small Phase I trials with a few sites to late-phase mega trials with thousands of sites and patients on the Medidata Platform.

- Assure a solid clinical research foundation with a leading, integration-friendly clinical platform and expert professional services and support.

- Partner for continued growth by gaining scalability and streamlining the journey to regulatory approval.

- Leverage high-data quality driven by real-time validation and coding accuracy.

Features of Rave Lite for Phase I Trials

Centralized Administration

Manage users, roles, studies, and sites across all Rave EDC (and other products on the Medidata Platform) studies through Platform Administration.

Intelligent Coding

Code verbatim terms automatically or manually with coding suggestions through **Rave Coder**.

Bulk Actions

Eliminate repetitive clicking to set data statuses, speeding up data entry and verification by Data and Study Managers.

Reporting and Analytics

Make informed decisions with real-time study insights through dashboards and standard/ad-hoc reports, and one-click access from reports to relevant forms.

Phase I Experience

Execute your Phase I study with agility, scale seamlessly, and automate key processes with Rave Lite for Phase I Trials.

1,000+ Customers | **10,000+** Studies

The Medidata Advantage

The world's leading biopharmaceutical and clinical research organizations choose Medidata because they trust our unparalleled experience and expertise in providing clinical trial technologies to over 35,000 studies with over 10 million patients and healthy volunteers. Rave EDC is the most preferred and used EDC system, and is recognized as the market leader*.

Users can execute with agility, work with the cleanest data, easily scale when needed, and gain confidence that no matter the size or complexity of your trial, Medidata provides a cost-effective offering to meet your trial's needs no matter the size or complexity.

*Source: EDC Benchmarking and Market Dynamics (5th Ed.), Industry Standard Research, June 2023.